These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

229 related articles for article (PubMed ID: 17073629)

  • 21. Longitudinal study on mitochondrial effects of didanosine-tenofovir combination.
    López S; Negredo E; Garrabou G; Puig J; Ruiz L; Sanjurjo E; Ramos X; Infante AB; Casademont J; Cardellach F; Clotet B; Miró O
    AIDS Res Hum Retroviruses; 2006 Jan; 22(1):33-9. PubMed ID: 16438643
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Suboptimal CD4 gains in HIV-infected patients receiving didanosine plus tenofovir.
    Barreiro P; Soriano V
    J Antimicrob Chemother; 2006 May; 57(5):806-9. PubMed ID: 16531427
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Nucleoside analogue mutations and Q151M in HIV-1 subtype A/E infection treated with nucleoside reverse transcriptase inhibitors.
    Sirivichayakul S; Ruxrungtham K; Ungsedhapand C; Techasathit W; Ubolyam S; Chuenyam T; Emery S; Cooper D; Lange J; Phanuphak P
    AIDS; 2003 Sep; 17(13):1889-96. PubMed ID: 12960821
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Clinical data II. Clinical experience of tenofovir DF in combination with protease inhibitors].
    Pulido F; Fiorante S
    Enferm Infecc Microbiol Clin; 2008 Jun; 26 Suppl 8():13-8. PubMed ID: 19195433
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Thymidine analogue-sparing highly active antiretroviral therapy (HAART).
    Nolan D; Mallal S
    J HIV Ther; 2003 Feb; 8(1):2-6. PubMed ID: 12840707
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Conclusions. Tenofovir].
    Mallolas J
    Enferm Infecc Microbiol Clin; 2008 Jun; 26 Suppl 8():62-4. PubMed ID: 19195439
    [No Abstract]   [Full Text] [Related]  

  • 27. HIV-1 resistance profile of the novel nucleoside reverse transcriptase inhibitor beta-D-2',3'-dideoxy-2',3'-didehydro-5-fluorocytidine (Reverset).
    Geleziunas R; Gallagher K; Zhang H; Bacheler L; Garber S; Wu JT; Shi G; Otto MJ; Schinazi RF; Erickson-Viitanen S
    Antivir Chem Chemother; 2003 Jan; 14(1):49-59. PubMed ID: 12790516
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Didanosine: an updated review of its use in HIV infection.
    Perry CM; Noble S
    Drugs; 1999 Dec; 58(6):1099-135. PubMed ID: 10651392
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Intracellular nucleotide levels during coadministration of tenofovir disoproxil fumarate and didanosine in HIV-1-infected patients.
    Hawkins T; Veikley W; Durand-Gasselin L; Babusis D; Reddy YS; Flaherty JF; Ray AS
    Antimicrob Agents Chemother; 2011 Apr; 55(4):1549-55. PubMed ID: 21282432
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Simplification therapy with once-daily didanosine, tenofovir and efavirenz in HIV-1-infected adults with viral suppression receiving a more complex antiretroviral regimen: final results of the EFADITE trial.
    Barrios A; Negredo E; Domingo P; Estrada V; Labarga P; Asensi V; Morales D; Santos J; Clotet B; Soriano V;
    Antivir Ther; 2005; 10(7):825-32. PubMed ID: 16312178
    [TBL] [Abstract][Full Text] [Related]  

  • 31. In vitro analysis of synergism and antagonism of different nucleoside/nucleotide analogue combinations on the inhibition of human immunodeficiency virus type 1 replication.
    Perez-Olmeda M; Garcia-Perez J; Mateos E; Spijkers S; Ayerbe MC; Carcas A; Alcami J
    J Med Virol; 2009 Feb; 81(2):211-6. PubMed ID: 19107982
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Quadruple nucleoside therapy with zidovudine, lamivudine, abacavir and tenofovir in the treatment of HIV.
    Stürmer M; Staszewski S; Doerr HW
    Antivir Ther; 2007; 12(5):695-703. PubMed ID: 17713153
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Hydroxyurea in combination with didanosine and stavudine in antiretroviral-experienced HIV-infected subjects with a review of the literature.
    Rossero R; Asmuth DM; Grady JJ; McKinsey DS; Green S; Andron L; Pollard RB
    Int J STD AIDS; 2003 May; 14(5):350-5. PubMed ID: 12803944
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Conserved T cell and natural killer cell function in treatment-experienced adults receiving tenofovir plus didanosine as nucleoside reverse transcription inhibitor backbone.
    Costa P; Bozzano F; Fenoglio D; Beltrame A; Cenderello G; Di Biagio A; Ferrea G; Pagano G; De Maria A
    Clin Exp Immunol; 2009 Oct; 158(1):55-63. PubMed ID: 19737231
    [TBL] [Abstract][Full Text] [Related]  

  • 35. K65R with and without S68: a new resistance profile in vivo detected in most patients failing abacavir, didanosine and stavudine.
    Røge BT; Katzenstein TL; Obel N; Nielsen H; Kirk O; Pedersen C; Mathiesen L; Lundgren J; Gerstoft J
    Antivir Ther; 2003 Apr; 8(2):173-82. PubMed ID: 12741630
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Stavudine plus a non-thymidine nucleoside reverse transcriptase inhibitor as a backbone for highly active antiretroviral therapy.
    Clumeck N
    Antivir Ther; 1998; 3 Suppl 4():39-43. PubMed ID: 10723508
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Tenofovir DF in rescue regimens].
    López Bernaldo de Quirós JC
    Enferm Infecc Microbiol Clin; 2008 Jun; 26 Suppl 8():25-30. PubMed ID: 19195435
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Rilpivirine versus efavirenz with tenofovir and emtricitabine in treatment-naive adults infected with HIV-1 (ECHO): a phase 3 randomised double-blind active-controlled trial.
    Molina JM; Cahn P; Grinsztejn B; Lazzarin A; Mills A; Saag M; Supparatpinyo K; Walmsley S; Crauwels H; Rimsky LT; Vanveggel S; Boven K;
    Lancet; 2011 Jul; 378(9787):238-46. PubMed ID: 21763936
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Tenofovir-containing nucleoside/nucleotide-only antiretroviral maintenance therapy: decision making and virological outcome.
    Buehlmann M; Chave JP; Flepp M; Schiffer V; Keiser O; Furrer H
    HIV Clin Trials; 2006; 7(2):48-54. PubMed ID: 16798619
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Early virologic failure in HIV-1 infected subjects on didanosine/tenofovir/efavirenz: 12-week results from a randomized trial.
    Maitland D; Moyle G; Hand J; Mandalia S; Boffito M; Nelson M; Gazzard B
    AIDS; 2005 Jul; 19(11):1183-8. PubMed ID: 15990571
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.